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Background: Hypercapnic ventilatory response (HCVR) techniques have not previously been
adequately validated in patients with chronic obstructive pulmonary disease (COPD). We have
tested the hypothesis that end-tidal PCO2 may be used to test the HCVR in COPD during non-
steady-state rebreathing, despite the fact that large (arterialeend-tidal) PCO2 differences
(P(aeet)CO2) exist during air breathing.
Methods: Eight patients and 11 healthy volunteers underwent steady-state HCVR testing and
non-steady-state rebreathing HCVR testing, using Pa and PetCO2.
Results: In COPD patients, PetCO2 was lower than PaCO2 by a constant amount throughout
steady-state HCVR, but equalised with PaCO2 during non-steady-state HCVR. Consequently
there were no differences in HCVR slope using either method (steady-state pZ 0.91; rebreath-
ing pZ 0.73), or HCVR intercept in rebreathing (pZ 0.68) whether PaCO2 or PetCO2 was used.
The steady-state HCVR intercept using PetCO2 was greater than that using PaCO2 (pZ 0.02). In
healthy volunteers PetCO2 equalised with PaCO2 during steady-state HCVR, but was progres-
sively greater than PaCO2 during non-steady-state. Consequently, there was no difference in
HCVR slope (pZ 0.21) or intercept (pZ 0.46) whether PaCO2 or PetCO2 was used. During non-
steady-state there was a P(aeet)CO2 difference in slope (pZ 0.03) and intercept (pZ 0.04).re for Respiratory Medicine, Churchill Hospital, Old Road, Headington, Oxford OX3 7LJ, UK. Tel.: þ44
221.
rg.uk (A.H. Nickol).
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HCVR assessment in COPD 259Conclusions: In COPD patients non-steady-state HCVR using PetCO2 is well tolerated, which is as
accurate as PaCO2. HCVR slope may be derived using PetCO2 during steady-state testing, though
there may be errors in intercept compared to use of PaCO2. In healthy volunteers PetCO2 may be
used to estimate PaCO2 during steady-state but not rebreathing HCVR.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
The hypercapnic ventilatory response (HCVR) provides
information on chemosensitivity.1,2 It can also be used to
investigate mechanisms leading to respiratory failure.3 In
particular, it has been utilised to examine the effects of
long-term domiciliary nocturnal non-invasive ventilation
(NIV) on gas exchange in patients with symptomatic
hypercapnic respiratory failure.4e6 These studies suggest
that measurements of HCVR may be of use in targeting
treatments in patients with respiratory failure. However,
presently there is no quick and easy method of assessing
HCVR that has been and well validated in patients with
respiratory failure and chronic obstructive pulmonary
disease (COPD).
Measurement of the HCVR is dependent on precise
measurements of PaCO2. In COPD patients the end-tidal
PCO2 (PetCO2), which is often used as a surrogate measure
of PaCO2,
7 is known to be a poor estimator of arterial PCO2.
This is due to prolonged P(aeet)CO2 equilibration times and
increased dead space,8,9 which leads to an attenuated
PetCO2 and a large P(aeet)CO2 difference at rest. How this
difference varies during different methods of measuring
HCVR is unknown. The accurate assessment of the HCVR is
also compromised in COPD patients due to poor neuro-
mechanical coupling, which attenuates the translation of
central ventilatory drive into alveolar ventilation.10 These
issues are magnified by factors that commonly co-exist in
COPD patients with hypercapnic respiratory failure, such as
obesity. We have therefore chosen to study patients with
hypercapnic respiratory failure secondary to COPD and
obesity.
HCVR can be measured using steady-state and non-
steady-state techniques. The traditional steady-state
technique is carried out by varying the concentration of
inspired CO2 until steady-state ventilation is attained.
11,12
This method is lengthy and poorly tolerated. Another
quicker and easier steady-state method, known as the Fenn
and Craig technique, has been developed.13e15 It involves
bleeding in fixed flow rates of CO2 in step-wise increasing
amounts every 5 min whilst measuring ventilation.16 It has
the advantage that delivered CO2 load is independent of
ventilation. A further advantage of this method is that the
HCVR is measured close to normal physiological CO2 levels.
The Read rebreathing technique is a non-steady-state
method of assessing the HCVR.17 It is widely used clini-
cally18,19 and in research.20e22 It is even quicker than the
non-steady-state tests, easy to perform and well tolerated.
The disadvantage of the technique is that the HCVR is
measured well above eucarbia, with the assumption that
the slope of the HCVR is linear and can be extrapolated. In
healthy volunteers rebreathing typically produces a higher
HCVR compared to steady-state techniques.17,23,24 We are
unaware however, of any studies in patients withrespiratory failure which have validated the use of PetCO2
during either steady-state or non-steady-state techniques.
The aim of the present study is to establish a quick and
easy technique for measuring HCVR in patients with COPD.
We therefore assessed the utility of PetCO2 for testing HCVR
during both steady-state and non-steady-state in COPD
patients, and healthy volunteers. We reasoned that during
the steady-state HCVR there would be a large P(aeet)CO2
difference in patients with COPD, but that this would be
attenuated during non-steady-state, since mixed venous
PCO2 (reflected by PetCO2) and PaCO2 would approach an
equilibrium. Thus we tested the hypotheses that HCVR slope
and intercept derived using PetCO2 (HCVRet) would provide
an adequate estimate of that derived using PaCO2 (HCVRa) in
patients with COPD using the non-steady-state Read
rebreathing technique, but not the steady-state Fenn and
Craig technique.
Methods
Subjects
Eight COPD patients with hypercapnic respiratory failure
and 11 healthy volunteers were studied. Patients had been
established on NIV for control of symptoms of hypo-
ventilation and improvement in gas exchange for at least 3
months. Subjects underwent measurement of height,
weight and screening spirometry; no healthy volunteers had
evidence of cardio-pulmonary disease (on history or lung
function), and all were non-smokers. Absolute contraindi-
cations were: any evidence of valvular heart disease,
a history of previous advice to take prophylactic antibiotics
prior to dental or other minor procedures, a history or
examination suggestive of poor circulation to the hand or
uni-arterial supply or vaso-vagal tendency. The study was
approved by the ethics committee of the Royal Brompton
and Harefield NHS Trust, and all subjects gave written
informed consent.
Techniques
Subjects sat comfortably reclining, breathing through
a well-sealed full-facemask (Fleximask, 0611 V, B and D
Electromedical, Stratford-Upon-Avon, Warwickshire, UK).
In some patients prominent facial creases made it difficult
to form a good seal, and so a mouthpiece and nose clip
were used. The facemask or mouthpiece was connected to
a pneumotachograph (3700 Hans Rudolf Inc, Missouri, USA)
and a non-rebreathing respiratory valve (Model 3700 Hans
Rudolph Inc, Missouri, USA) with a combined dead space of
215 mls. The integrated flow signal from a pressure trans-
ducer (MP 45, 2.25 cm H2O, Validyne, California, USA)
enabled determination of minute ventilation. Tidal PCO2
was measured using an infra-red CO2 analyser (Morgan
260 A.H. Nickol et al.Medical, Kent, England). The tip of the sampling tubing was
placed inside the nares (facemask) or connected to a side
port of the mouthpiece. Gas for sampling passed through
a 13 cm long drying tube (Nafion, Perma Pure Inc, Toms
River, New Jersey 08754, USA). Arterial oxygen saturation
was measured continuously using pulse oximetry (Nellcor N-
200 Pulse oximeter, Nellcor Inc, Pleasanton, California).
The oximeter had an averaging time of 5e7 s. A three lead
ECG (Diascope 2, S&W Medico Teknik A/S, Albertslund,
Denmark) was monitored by the clinician; no patients
developed ectopics or arrhythmias. Monitoring equipment
was shielded from view of the subjects and they watched
a video during the HCVR.
Fenn and Craig steady-state HCVR
The breathing circuit is illustrated in Fig. 1. The inspiratory
limb of the valve was connected to a three-way tap via
tubing (internal diameter 35 mm, length 1.50 m). The tap
could be turned so that the subject breathed from room air
or from an oxygen reservoir consisting of a 200-l Douglas
bag, which was continuously being filled with warmed and
humidified 100% oxygen. 100% CO2 could be bled into the
inspirate via a port near the respiratory valve at a low,
controlled flow rate. Subjects underwent a 10 min rest
period during which the inspiratory limb was connected to
room air. At the start of the steady-state test, the inspi-
ratory limb was switched to the oxygen reservoir, and 100%
CO2 was added to the inspirate at a rate of 200 mls/min for
5 min. The flow rate was increased in 200 mls/min incre-
ments every 5 min up to a maximum of 800 mls/min.Figure 1 Breathing circuit for the Fenn and Craig steady-
state hypercapnic ventilatory response. The subject starts by
breathing via a mask or mouthpiece from room air for 10 min. A
three-way tap is then turned so they breathe from humidified
100% oxygen. 100% CO2 is bled into the inspiratory airflow, at
progressive flow rates (200e800 mls/min) every 5 min. A
pneumotachograph measures airflow, integrated to give
ventilation breath by breath, and fine tubing in the nares
enables measurement of tidal PCO2.Arterial blood samples were taken at the end of minutes 9
and 10 of rest, and at the end of minutes 4 and 5 of each
CO2 increment.
Rebreathing HCVR
The breathing circuit is illustrated in Fig. 2. Subjects under-
went a 10 min period breathing room air. At the start of
rebreathing, a 6-l anesthetic bag containing 5% CO2 balance
oxygen was connected to the inspiratory limb, and tubing
joined the inspiratory and expiratory limbs in a circuit. Arte-
rial blood sampleswere takenat theendofminutes 9and10of
the rest period, and at the end of eachminute of rebreathing.
Arterial blood gas sampling and analysis
To enable repeated arterial blood gas sampling, an arterial
cannula (22G Abbocath, Abbot Ireland, Sligo, Republic of
Ireland) was inserted into the radial artery of the non-
dominant hand under local anesthetic (Lidocaine 1%,
Antigen Pharmaceuticals Ltd, Roscrea, Ireland) by
a consultant intensivist using an aseptic technique. It was
attached to a standard pressure transducer set (Edwards
Life Sciences, Irvine, CA 92614-5686 USA) including a three-
way tap for sampling arterial blood. A 250 ml bag of normal
saline (Baxter Health Care Ltd, Thetford, Norfolk, England)
pressurized to 300 mmHg was connected to the transducer
set. The dead space between the arterial catheter and
sampling port of the three-way tap was 0.5 mls. Arterial
blood samples of 2.5 mls were taken over approximately
4e7 s, with the start and end of each sampling period
marked on the data acquisition system. Immediately prior
to sampling, 1e1.5 mls of blood was withdrawn and dis-
carded. Samples were taken in pre-heparinized (Heparin
1000 U/ml, Leo Laboratories Ltd, Princes Risborough,
Bucks, HP27 9RR, UK) syringes. These were sealed imme-
diately with an airtight cap, and stored in crushed ice up to
a maximum of 30 min before analysis on an arterial bloodFigure 2 Breathing circuit for the Read rebreathing hyper-
capnic ventilatory response. The subject starts by breathing
via a mask or mouthpiece from room air for 10 min. A closed
circuit breathing system is then attached, which contains a 6-l
anesthetic bag filled with 5% CO2/balance oxygen. The subject
breathes through the closed circuit for 4 min. A pneumo-
tachograph measures airflow, integrated to give ventilation
breath by breath, and fine tubing in the nares enables
measurement of tidal PCO2.
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House, Strawberry Hill, Newbury, Berks, UK). The arterial
line was flushed with saline after each sample and the
patients hand was wrapped in a blanket to keep it warm.
Circulation time
An estimation of the (mouthelungehand) circulation time
wasmade to enable PaCO2 to be aligned to the corresponding
PetCO2. Subjects were asked to hold their breath at end-
expiration until breaking point (the point atwhich they could
hold their breath no longer), following which they took
a breath of 100% oxygen from a 6 l anesthetic bag and held
their breath for 5 s. The time taken from breaking point to
the start of the rise in SaO2 was taken to be equivalent to the
lungehand circulation time. This technique has been previ-
ously described to measure the lungeear circulation time,
with the pulse oximeter placed on the ear lobe.25
Protocol
Subjects refrained from caffeine for at least 4 h before the
study. They were assessed clinically and the arterial line
was then inserted. The HCVR testing, both steady-state
Fenn and Craig technique13 and modified Read rebreathing
technique17 were carried out in a randomised order with
>30 min between tests. In the breaks patients were
allowed snacks and non-caffeinated drinks.
Data analysis
Flow, PCO2 and SaO2 signals were recorded via an analogue
to digital interface (1401 Micro, Cambridge Electronic
Design Ltd, Cambridge, UK). The signals were then analysed
(Spike2, Cambridge Electronic Design Ltd, Cambridge, UK)
to provide breath-by-breath measurements of inspired
minute ventilation and PetCO2. Adjustments to standardise
measurements at body temperature, with fully saturated
water vapour pressure at 37 C were made. Breaths corre-
sponding to each arterial blood gas sample were deter-
mined by subtracting the (mouthelungehand) circulation
time from the start and end of each arterial blood sample
time. Measurements of circulation time were carried out in
all patients with COPD, but only 5 of 11 healthy volunteers
as it was not introduced into the protocol until after the
study was in progress. In the healthy volunteers in whom an
estimate was not made, a circulation time of 15 s was used.
Linear regression analysis of minute ventilation on PaCO2 or
PetCO2 was used to determine the hypercapnic ventilatory
response (HCVRa or HCVRet) slope (L/min/mmHg) and
intercept (mmHg) during steady-state testing and
rebreathing. The slope was also expressed in degrees for
statistical analysis. This enabled small variations in the
angle of the slope to be equally weighted irrespective of
a blunted HCVR (flat slope) or brisk HCVR (steep slope).
Sample size
The P(aeet)CO2 difference measured during air breathing
in 40 COPD patients with a similar severity of lung disease
compared to our group (FEV1 32% predicted, versus 34%
predicted in our study) has previously been observed to be7.0 5.2 mmHg.8 Assuming 80% power and significance at
the 0.05 level, a sample size of at least 6 would be required
to detect a similar difference in P(aeet)CO2 in our study.
Statistical analysis
Group results are given as mean SD, unless otherwise
stated. Unpaired t-tests were used to compare healthy
volunteers with COPD patients, and ANOVA to compare
sequential P(aeet)CO2 differences during the HCVR. Pear-
son’s correlation was used to examine the relationship
between steady-state and rebreathing HCVR, for the slope
and intercept.
HCVRa and HCVRet are compared using a BlandeAltman
plot26 both for the slope and intercept, in which (HCVRae
HCVRet) difference is plotted against the mean of HCVRa
and HCVRet. The horizontal axis crosses the vertical axis at
the mean (HCVRa HCVRet) difference, and 2SD above and
below the mean are denoted by dashed lines. If there is
good agreement between two parameters, the mean
difference is close to zero, and data points are tightly
clustered around this line. BlandeAltman plots have the
advantage over simple regression that they not only illus-
trate whether there is a relationship between two vari-
ables, but also whether it is close to unity (x-axis passes
through zero on the y-axis) or not (x-axis is displaced up or
down).
Analysis comparing P(aeet)CO2 during the steady-state
HCVR was carried out on six COPD patients up to 600 mls/
min and on eleven healthy volunteers up to 800 mls/min.
During non-steady-state HCVR, one of eight patients with
COPD and one of eleven healthy volunteers were unable to
complete minute 4 of the test. Therefore, analysis
comparing P(aeet)CO2 during rebreathing HCVR was
therefore carried out on seven patients with COPD and ten
healthy volunteers up to 4 min. Analysis of the HCVR was
carried out on all subjects (ie eight COPD patients and
eleven healthy volunteers), as three data points were
considered sufficient to determine the HCVR.
Results
Subject characteristics
Eight patients with hypercapnic COPD, established on NIV
for at least three months (five male) and eleven healthy
volunteers (seven male) were studied (Table 1). COPD
patients had a pack-year history of 43 (17) years (range 20e
60 years), with two being current smokers and six being ex-
smokers. None of the healthy volunteers had ever smoked.
The patients with COPD had obstructive spirometry, one
was overweight (defined as body mass index (BMI) 25e
29.9 kg/m2), and seven of eight were clinically obese
(BMI> 30 kg/m2). Four had symptoms suggestive of
obstructive sleep apnea prior to initiation of NIV. The COPD
patients had a group mean SD PaO2 of 58 7 mmHg, and
PaCO2 of 49 10 mmHg, while breathing room air through
a mouthpiece. The healthy volunteers were younger
(p< 0.001) had normal spirometry (FEV1 higher than COPD
patients, p< 0.001), normal arterial blood gases (PaO2
higher, p< 0.001; PaCO2 lower, pZ 0.01) and none had
Table 1 Characteristics of patients with COPD and healthy volunteers.
Age
(years)
Sex BMI
(kg/m2)
FEV1
(% Pred)
FVC
(% Pred)
FEV1/
FVC
PaO2
(mmHg)
PaCO2
(mmHg)
Circulation
time (s)
Healthy volunteers 29 F 22.8 98 105 80 102 43 18
31 M 24.0 105 104 85 105 39 22
36 M 21.5 117 119 82 116 41 17
37 F 24.3 105 125 73 105 34 e
34 M 25.7 95 97 83 102 43 e
29 M 29.4 91 90 85 96 42 e
32 M 24.7 101 104 81 102 42 e
23 F 20.9 78 77 89 98 41 e
29 F 24.7 102 100 89 100 40 13
25 F 17.9 99 92 95 106 38 e
24 M 25.5 95 96 83 108 40 17
Mean 30 23.8 99 101 84 104 40 17
SD 5 3.0 8 13 6 6 3 3
COPD patients 59 F 37.5 48 74 48 65 48 17
51 M 35.8 19 70 21 53 55 25
57 F 35.7 31 50 49 53 55 22
63 M 45.1 48 61 56 67 59 21
65 M 35.2 28 66 42 55 33 17
69 M 31.2 27 94 22 62 40 19
54 M 26.8 23 59 30 59 43 18
72 F 32.0 50 64 58 46 58 16
Mean 61 34.9 34 67 41 58 49 19
SD 7 5.3 12 13 15 7 10 3
262 A.H. Nickol et al.symptoms of obstructive sleep apnea. They also had
a significantly lower BMI than patients with COPD
(p< 0.001); three were overweight, but none were obese.
Comparison of arterial and end-tidal PCO2 during
air breathing and steady-state HCVR
Fig. 3 shows the mean and S.E.M. Pa and PetCO2 during air
breathing (first data point in each panel). Consistent with
previous reportsPetCO2was less thanPaCO2 (7.1 3.9 mmHg;
pZ 0.001) in COPD patients. In healthy volunteers, PetCO2
was greater than PaCO2 (1.4 1.4 mmHg; pZ 0.009). As
expected, the P(aeet)CO2 difference was greater in COPD
patients than healthy volunteers (p< 0.001).
In patients with COPD the P(aeet)CO2 difference
observed during air breathing was maintained during the
steady-state HCVR (Fig. 3, top left panel) and there was no
change in the magnitude of the difference as CO2 supple-
mentation was increased (pZ 0.44). Therefore there was no
difference between the HCVRa and HCVRet slope (pZ 0.91,
Table 2). This is shown in the BlandeAltman plot (Fig. 4, top
left panel) where the HCVRa HCVRet difference in slope is
plotted against the mean of HCVRa and HCVRet slope. Notice
that the data points for COPD patients are evenly distributed
either side of zero. The HCVRa intercept, however, was
greater than HCVRet intercept (pZ 0.02). This is shown in
Fig. 4 (bottom left panel) where data points for COPD
patients tend to be greater than zero. It should be noted
however that there was one extreme outlier (>2SD from the
group mean) for the plot of P(aeet)CO2 intercept during
steady-state HCVR (mean P(aeet)CO2 intercept: outlier179 mmHg, group mean 2SDZ146e154). This data
point was therefore were omitted from the BlandeAltman
plot (Fig. 4, bottom left panel) and from statistical analysis.
In the healthy volunteers, there was no difference
between PetCO2 and PaCO2 during steady-state HCVR
(Fig. 3, bottom left panel), and thus no difference between
the HCVRa and HCVRet slope (pZ 0.21; Table 2) or intercept
(pZ 0.46; Table 2). This is shown in Fig. 4 (left panels)
where data points for healthy volunteers are evenly
distributed around zero for both slope (top panel) and
intercept (bottom panel).
Comparison of arterial and end-tidal PCO2 during
the non-steady-state HCVR
In patients with COPD, the P(aeet)CO2 difference observed
during air breathing was abolished throughout the non-
steady-state HCVR (Fig. 3, top right panel). Therefore there
was no difference between the HCVRa and HCVRet slope
(pZ 0.73, Table 2) or intercept (pZ 0.68, Table 2). This is
shown in Fig. 4 (top right panel) where the data points for
COPD patients during rebreathing are evenly distributed
either side of zero. In contrast, in the healthy volunteers
the P(aeet)CO2 difference observed during air breathing
was maintained during the non-steady-state HCVR (Fig. 3,
bottom right panel). Post hoc analysis showed that the
magnitude of the P(aeet)CO2 difference varied throughout
the rebreathing (p< 0.001), with differences between
minutes 1 vs 3; 2 vs 3; and, 2 vs 4. As a consequence, there
was a significant difference between the HCVRa and HCVRet
slope (pZ 0.03; Table 2) and intercept (pZ 0.04; Table 2).
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Figure 3 Mean SEM arterial (closed circles) and end-tidal (open circles) PCO2 in mmHg during air breathing (normoxia) and
assessment of the hypercapnic ventilatory response (in hyperoxia). Values for COPD patients (top panels), healthy volunteers
(bottom panels), steady-state CO2 administration (left panels) and rebreathing (right panels) are shown. Significance at the 0.01
and 0.05 levels are denoted y and *, respectively.
Table 2 HCVR slope and intercept for steady-state and non-steady-state rebreathing methods, using arterial and end-tidal
PCO2
Steady-state HCVR,
Fenn and Craig method
Non-steady-state HCVR,
Read Rebreathing method
Slope (L/min/mmHg) Intercept (mmHg) Slope (L/min/mmHg) Intercept (mmHg)
COPD HCVRa 0.61 0.32 33.6 19.2 0.52 0.40 20.0 19.3
HCVRet 0.62 0.36 26.1 5.9 0.53 0.40 18.5 17.7
p value 0.91 0.02 0.73 0.68
Volunteers COPD HCVRa 2.19 1.06 31.5 5.11 2.77 2.49 39.8 6.35
HCVRet 1.97 1.01 30.9 5.6 2.15 1.64 41.7 4.7
p value 0.21 0.46 0.03* 0.04*
Mean SD HCVR slope (in L/min/mmHg) and intercept (in mmHg), using arterial (HCVRa) and end-tidal PCO2 (HCVRet). In COPD patients,
for the HCVR slope during steady-state testing nZ 6, and during non-steady-state testing nZ 8; in the healthy volunteers nZ 11 for
both methods. For the HCVR intercept in COPD patients one outlier (>2 SD from the mean) was omitted from the analysis of the data
obtained during both steady-state testing (nZ 5) and non-steady-state testing (nZ 7). Significance values comparing HCVRa and
HCVRet, using paired t-tests are given. Significance at the 0.05 level is denoted*.
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Figure 4 BlandeAltman plots showing the HCVRa HCVRet difference (vertical axes) versus mean HCVRa and HCVRet (horizontal
axes) for healthy volunteers (closed circles) and COPD patients (open circles). The dotted lines represent 2 SD above and below the
mean arterial to end-tidal HCVR differences for healthy volunteers. The slope in degrees (top panels), intercept in mmHg (bottom
panels), steady-state (left panels) and rebreathing (right panels) are shown. One extreme outlier (>2 SD from the group mean) for
P(aeet)CO2 differences in intercept has been omitted for steady-state HCVR, and one for rebreathing HCVR.
264 A.H. Nickol et al.This is shown in Fig. 4 (right panels) where data points for
healthy volunteers tend to be greater than zero for the
slope (top right panel), and less than zero for the intercept
(bottom right panel).
There was one extreme outlier (>2SD from the group
mean) for the plot of P(aeet)CO2 intercept during non-
steady-state HCVR (mean P(aeet)CO2 intercept: outlier
77 mmHg, group mean 2SDZ69e83). This data point
was therefore were omitted from the BlandeAltman plot
(Fig. 4, bottom right panel) and from statistical analysis.
Comparison of steady-state and non-steady-state
HCVR measured using PaCO2 or PetCO2
Comparing the steady-state with the non-steady-state
HCVR in COPD patients there was no difference in slope or
intercept derived using PaCO2 (HCVRa slope pZ 0.59,
intercept 0.74) or PetCO2 (HCVRet slope pZ 0.58, intercept
0.91). In healthy volunteers there was also no difference inslope derived using PaCO2 (HCVRa slope pZ 0.92) or PetCO2
(HCVRet slope pZ 0.90), however, the intercept was
significantly higher with the non-steady-state rebreathing
technique derived using PaCO2 (HCVRa intercept pZ 0.001)
and PetCO2 (HCVRet intercept <0.001).
Discussion
We have shown that in patients with COPD and obesity the
HCVR slope can be accurately measured using PetCO2 or
PaCO2 during both steady-state and, non-steady-state
techniques, and therefore either method may be used
clinically to determine the slope. We did find a difference
in the HCVR intercept with the steady-state method, but
not with the non-steady-state rebreathing. Therefore the
rebreathing technique is the method of choice when HCVR
intercept is of interest. In contrast, in healthy volunteers,
assessment of the HCVR using the steady-state technique is
preferable. This is because during steady-state HCVR, the
HCVR assessment in COPD 265P(aeet)CO2 difference was abolished, and there was no
difference in HCVR slope or intercept using PetCO2 or
PaCO2. Whereas during rebreathing, PetCO2 was greater
than PaCO2 by a varying amount, leading to differences in
both HCVR slope and intercept. The large P(aeet)CO2
difference during air breathing at rest in COPD patients is
consistent with previous reports.8,9 Our results should be
interpreted with caution due to the small sample size,
however they are consistent with expected findings.
P(aeet)CO2 differences in COPD patients
The reduced PetCO2 compared to PaCO2 during air
breathing in patients with COPD is explained by expired
gas from ventilated but under-perfused units of lung
with low PCO2 content diluting the expired PCO2 frac-
tion. As such, the single greatest determinant of the
P(aeet)CO2 difference has been shown to be tidal
volume,27 since a large tidal volume to dead space ratio
will reduce the dilutional effect of returning gas from
under-perfused lung units.
During air breathing and steady-state HCVR, PetCO2 was
lower than PaCO2 in patients with COPD. As a consequence
the steady-state HCVRet intercept was significantly less
than the HCVRa intercept. Since the P(aeet)CO2 difference
was constant, there was no difference in HCVR slope. By
contrast during non-steady-state HCVR testing the
P(aeet)CO2 difference was abolished, as would be expec-
ted since during rebreathing mixed venous PCO2 (reflected
by PetCO2) and PaCO2 approach an equilibrium. There was
therefore no difference in non-steady-state HCVRa or
HCVRet intercept or slope. Our observations during
rebreathing are in keeping with previous studies in COPD
patients.28 We have extended this study by showing that
there is no difference in slope between steady-state and
rebreathing techniques in the patients with COPD. This is in
agreement with one previous study in healthy subjects,17
although a number of others have tended to show a higher
rebreathing HCVR compared to the steady-state23,24,29
again in healthy subjects.
P(aeet)CO2 differences in healthy volunteers
PetCO2 was slightly higher than PaCO2 during resting
breathing (1.4 1.4 mmHg) in healthy volunteers. This is the
opposite result of some30e33 but not all34 previous studies in
man. The reason for our observation is not clear; however,
we have suggested several contributorymechanisms. Firstly,
the respiratory cycle generates oscillations in alveolar PCO2,
which in turn lead to oscillations in arterial PCO2.
35 Whereas
PetCO2 reflects the peak of the oscillation, PaCO2 of a sample
drawn over several breath cycles reflects the mean of the
oscillation. In this way PetCO2 could be greater than PaCO2.
This suggestion is supported by the observation that during
exercise PaCO2 oscillations increase in magnitude,
36 and at
higher work intensities PetCO2 becomes greater than
PaCO2.
27,37 To our knowledge this relationship has not
previously been observed at rest. In our study such an effect
may have been unmasked by body posture since subjects
were tested in the semi-recumbent position rather than
upright. A change in posture from standing to supine leads to
decreased alveolar dead space, presumably due to thegravitational effect on blood flow in the pulmonary blood
vessels leading to better ventilationeperfusion matching,38
and therefore an increase in PetCO2 relative to PaCO2.
39,40 In
addition, the 215 ml respiratory apparatus dead space in our
study may have caused a degree of rebreathing, thereby
raising PetCO2. During the HCVR assessment we would not
expect PCO2 oscillations to play an important role in the
P(aeet)CO2 relationship, since the inhaled CO2 load would
attenuate the oscillation profile.
During steady-state HCVR testing the P(aeet)CO2
difference during air breathing in healthy subjects was
abolished. There was therefore no difference in HCVRa or
HCVRet slope or intercept. However, during non-steady-
state HCVR testing the P(aeet)CO2 difference was main-
tained, with PetCO2 being higher in healthy volunteers
during HCVR testing, as shown previously.30,31,41 There was
a difference in both HCVRa and HCVRet slope and inter-
cept. It has previously been speculated that the higher
PetCO2 during rebreathing in healthy volunteers may arise
due to failure of CO2/HCO3
 reactions to complete during
the passage of blood through the lungs; if the reaction
completes ‘downstream’ by the point of arterial blood
sampling, PaCO2 will be lower.
30,42,43 Interestingly Stein-
brook et al.41 in awake goats only found PetCO2 to be
higher than PaCO2 during rebreathing under hyperoxic
conditions, but not during normoxia. They attributed this
to regional variations in alveolar gas composition which
accompanies rebreathing.Limitations of the study
When interpreting the findings of our study it must be noted
that although circulation time was measured at rest in all
patients, it was only measured in 5 of the 11 healthy
volunteers. Since circulation time at rest is likely to differ
to that measured during HCVR assessment this may have
influenced the P(aeet)CO2 relationships described in this
study. However, we think that the influence of this inac-
curacy is likely to be so small that it would not change the
P(aeet)CO2 relationships described. For example, during
rebreathing the average increase in PetCO2 from minutes 1
to 4 was 19 mmHg for patients with COPD and 9 mmHg for
healthy volunteers. Therefore, an error in the estimation of
the circulation time of 5 s, would have led to an error in
PetCO2 corresponding to the time of arterial blood gas
sampling of 0.5 mmHg for patients with COPD and
0.3 mmHg for the healthy volunteers.
We did not attempt to match COPD patients and volun-
teers for age. Ventilatory responses tend to decrease with
age,2 however, it was not the aim of this study to compare
HCVR between the healthy volunteers and COPD patients.
The same inspired CO2 load was used both for healthy
volunteers and for COPD patients, despite the fact the
baseline PCO2 for COPD patients was higher. The initial
CO2 stimulus for volunteers would therefore be relatively
greater than for patients. This simple approach was
taken rather than the much more experimentally
complex approach of adjusting the starting FiCO2 for
each individual. It would have delayed the equilibration
time in COPD patients, but should not affect HCVR
slope.
266 A.H. Nickol et al.Conclusions and implications of findings
Our study shows that even in patients with severe respira-
tory disease, such as those with hypercapnic respiratory
failure secondary to COPD and obesity a valid measurement
of HCVR can be made, which is quick and easy to perform.
Despite large P(aeet)CO2 differences observed at rest,
PetCO2 can be used during assessment of both the steady-
state and an non-steady-state breathing HCVR slope in
patients with COPD. Therefore, since both methods are
non-invasive, relatively short and can be tolerated by
patients with severe respiratory failure, either method is
practical and may be used in clinical practice. The non-
steady-state rebreathing method is preferred if the inter-
cept is of particular interest. In healthy volunteers the
steady-state HCVR is preferable.
Conflict of interest
The authors have no conflicts of interest.Acknowledgements
This research was supported by grants from the Wellcome
Trust and the Hammersmith Hospitals Trustees’ Research
Committee.
References
1. Filley G, Swanson G, Kindig N. Chemical breathing controls:
slow, intermediate and fast. Clin Chest Med 1980;1(1):13e32.
2. Browne H, Adams L, Simonds A, Morrell M. Ageing does not
influence the sleep-related decrease in the hypercapnic
ventilatory response. Eur Respir J 2003;21:523e9.
3. Dunroy H, Adams L, Corfield D, Morrell M. CO2 retention in lung
disease; could there be a pre-existing difference in respiratory
physiology. Respir Physiol Neurobiol 2003;136:179e86.
4. Elliott M, Mulvey D, Moxham J, Green M, Branthwaite M.
Domiciliary nocturnal nasal intermittent positive pressure
ventilation in COPD: mechanisms underlying changes in arterial
blood gas tensions. Eur Respir J 1991;4:1044e52.
5. Nickol A, Hart N, Hopkinson N, Hamnegard C-H, Moxham J,
Simonds A, et al. Mechanisms of improvement of respiratory
failure in patients with COPD treated with NIV. Int J Chron
Obstruct Pulmon Dis Aug 15, 2008 [Epub ahead of print].
6. Nickol A, Hart N, Hopkinson N, Moxham J, Simonds A, Polkey M.
Mechanisms of improvement of respiratory failure in patients
with restrictive thoracic disease treated with non-invasive
ventilation. Thorax 2005;60(9):754e60.
7. Thomson S, Morrell M, Cordingley J, Semple S. Ventilation is
unstable during drowsiness before sleep onset. J Appl Physiol
2005;99:2036e44.
8. Kowalski J. Arterial to end-tidal CO2 partial pressure gradient and
the functionaldeadspace inpatientswithobstructiveor restrictive
lung diseases. Bull Physiopathol Respir (Nancy) 1966;2:539e44.
9. Poppius H, Korhonen O, Viljanen A, Kreus K. Arterial to end-
tidal CO2 differences in respiratory disease. Scand J Respir Dis
1975;56:254e62.
10. Whitelaw W. Assessment of output of the respiratory
controller. Semin Respir Crit Care Med 1998;19(4):361e5.
11. Nielsen M, Smith H. Studies on the regulation of respiration in
acute hypoxia; with an appendix on respiratory control during
prolonged hypoxia. Acta Physiol Scand 1952;24(4):293e313.12. Lloyd B, Jukes M, Cunningham D. The relation between alve-
olar oxygen pressure and the respiratory response to carbon
dioxide in man. Q J Exp Physiol Cogn Med Sci 1958;43(2):
214e27.
13. Fenn WO, Craig AB. Effect of CO2 on respiration using a new
method of administering CO2. J Appl Physiol 1963;18(5):
1023e4.
14. McConnell A, Semple E. Ventilatory sensitivities to carbon
dioxide: the influence of exercise and athleticism. Med Sci
Sports Exerc 1996;28(6):685e91.
15. Warley A, Clarke M, Phillips T, Stradling J. Ventilatory response
to an inhaled constant CO2 load and added dead space in
healthy men, awake and asleep. Respir Physiol 1989;75:
183e92.
16. Saunders K. A breathing model of the respiratory system: the
controlled system. J Theor Biol 1980;84:135e61.
17. Read D. A clinical method for assessing the ventilatory
response to carbon dioxide. Australas Ann Med 1967;16:
20e32.
18. Beecroft J, Duffin J, Pierratos A, Chan C, McFarlane P, Hanly P.
Enhanced chemo-responsiveness in patients with sleep apnoea
and end-stage renal disease. Eur Respir J 2006;28:151e8.
19. Zandbergen J, Pols H, Loof Cd, Griez E. Ventilatory response to
CO2 in panic disorder. Psychiatry Res 1991;39(1):13e9.
20. Whitelaw WA, Derenne JP, Milic-Emili J. Occlusion pressure as
a measure of respiratory center output in conscious man.
Respir Physiol 1975;23:181e99.
21. Rebuck A, Campbell E. A clinical method for assessing the
ventilatory response to hypoxia. Am Rev Respir Dis 1974;109:
345e50.
22. McGurk S, Blanksby B, Anderson M. The relationship of hyper-
capnic ventilatory response to age, gender and athleticism.
Sports Med 1995;19(3):173e83.
23. Berkenbosch A, Bovill J, Dahan A, DeGoede J, Olievier I. The
ventilatory CO2 sensitivities from Read’s re e breathing
method and the steady-state method are not equal in man. J
Physiol 1989;411:367e77.
24. Mohan R, Amara C, Cunningham D, Duffin J. Measuring central-
chemoreflex sensitivity in man: rebreathing and steady-state
methods compared. Respir Physiol 1999;115:23e33.
25. Fowler W, Comroe J. Lung function studies. I. The rate of
increase of arterial oxygen saturation during the inhalation of
100 percent O2. J Clin Invest 1948;27:327e34.
26. Bland J, Altman D. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986;
1(8476):307e10.
27. Jones N, Robertson D, Kane J. Difference between end-tidal
and arterial PCO2 in exercise. J Appl Physiol 1979;4(5):
954e60.
28. McEvoy J, Jones N, Campbell E. Alveolar-arterial PCO2 differ-
ences during rebreathing in patients with chronic hypercapnia.
J Appl Physiol 1973;35(4):542e5.
29. Jacobi M, Patil C, Saunders K. Transient, steady-state and
rebreathing responses to carbon dioxide in man, at rest and
during light exercise. J Physiol 1989;411:85e96.
30. Jones N, Robertson D, Kane J, Campbell E. Effect of PCO2 level
on alveolar-arterial PCO2 difference during rebreathing. J Appl
Physiol 1972;32(6):782e7.
31. Laszlo G, Clark T, Pope H, Campbell E. Differences between
alveolar and arterial PCO2 during rebreathing experiments in
resting human subjects. Respir Physiol 1971;12:36e52.
32. Tojima H, Kuriyama T, Fukuda Y. Arterial to end-tidal PCO2
differences varies with different ventilatory conditions during
steady state hypercapnia in the rat. Jpn J Physiol 1988;38:
445e57.
33. Robbins P, Conwway J, Cunningham D, Khamnei S, Paterson D.
A comparison of indirect methods for continuous estimation of
arterial PCO2 in men. J Appl Physiol 1990;68(4):1721e31.
HCVR assessment in COPD 26734. Liu Z, Vargas F, Stansbury D, Sasse S, Light R. Comparison of
the end-tidal arterial PCO2 gradient during exercise in normal
subjects and in patients with severe COPD. Chest 1995;107:
1218e24.
35. Band D, Semple S. Continuous measurement of blood pH with
an indwelling glass electrode. J Appl Physiol 1967;22:858e60.
36. Band D, Wolff C, Ward J, Cochrane G, Prior J. Respiratory
oscillations in arterial in carbon-dioxide tension as a control
signal in exercise. Nature 1980;283:84e5.
37. Whipp B, Wasserman K. Alveolar-arterial gas tension differ-
ences during graded exercise. J Appl Physiol 1969;27(3):
361e5.
38. West J. Distribution of blood flow and ventilation-perfusion
ratio in the lung, measured with radioactive CO2. J Appl
Physiol 1960;15:405e10.39. Bjurstedt H, Hesser H, Liljestrand G, Matell G. Effects of posture
on alveolar-arterial CO2 andO2 differences and on alveolar dead
space in man. Acta Physiol Scand 1962;54:65e82.
40. Forster H, Pan L, Funahashi A. Temporal pattern of arterial CO2
partial pressure during exercise in humans. J Appl Physiol
1986;60(2):653e60.
41. Steinbrook R, Fencl V, Gabel R, Leith D, Weinberger S. Reversal
of arterial-to-expired CO2 partial pressure differences during
rebreathing in goats. J Appl Physiol 1983;55(3):736e41.
42. Forster R, Crandall E. Time course of exchanges between red
cells and extracellular fluid during CO2 uptake. J Appl Physiol
1975;38(4):710e8.
43. Bidani A, Crandall E. Analysis of PCO2 differences during
rebreathing due to slow pH equilibration in blood. J Appl
Physiol 1978;45(5):666e73.
